NIMBEX

PreclinicalSmall molecule

AAssistance Publique Hopitaux De Marseille

NIMBEX is one of 3 small molecule programs targeting Thoracic Paravertebral Block. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thoracic Paravertebral BlockCompleted

Thoracic Paravertebral BlockPreclinical

Completed

Competition

Competitive Landscape

8 competitors in Thoracic Paravertebral Block

#DrugCompanyPhaseTrials

NIMBEX

AAssistance Publique Hopitaux De Marseille

Preclinical

1 2

Sevorane

SSilesian University of Medicine

Preclinical

1 3

Oxynorm

MMundipharma (China) Pharmaceutical Co. Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thoracic Paravertebral Block1 trial

Thoracic Paravertebral Block in Pain Management After Renal Surgery

Completed·SSilesian University of Medicine·N/A·NCT02840526·58 enrolled

Acute Respiratory Distress Syndrome1 trial

Effects of Neuromuscular Blocking Agents (NMBA) on the Alteration of Transpulmonary Pressures at the Early Phase of Acute Respiratory Distress Syndrome (ARDS)

Unknown status·AAssistance Publique Hopitaux De Marseille·Phase 4·NCT01573715·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NIMBEX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NIMBEX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NIMBEX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique Hopitaux De Marseille company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique Hopitaux De Marseille

NIMBEX

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thoracic Paravertebral Block1 trial

Acute Respiratory Distress Syndrome1 trial

References

Drug Info

Quick Facts

Related News